* AtriCure Inc ATRC.OQ ATRC.O is expected to show a rise in
quarterly revenue when it reports results on August 4.
* The Mason, Ohio-based company is expected to report a
49.6% increase in revenue to $61.075 million from $40.82 million
a year ago, according to the mean estimate from 8 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for AtriCure Inc is for a
loss of 33 cents per share. For the same quarter last year, the
company reported a loss of 20 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for AtriCure Inc is
$86, about 2% above its last closing price of $84.25.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 -0.37 -0.37 -0.38 Missed -3.5
Dec. 31 2020 -0.27 -0.28 -0.28 Met 0.6
Sep. 30 2020 -0.32 -0.34 -0.11 Beat 67.6
Jun. 30 2020 -0.56 -0.57 -0.20 Beat 64.9
Mar. -0.40 -0.41 -0.42 Missed -3.5
31 2020
Dec. 31 2019 -0.41 -0.41 -0.42 Missed -1.2
Sep. 30 2019 -0.30 -0.27 -0.25 Beat 8.1
Jun. 30 2019 -0.17 -0.18 -0.11 Beat 37.6
This summary was machine generated August 2 at 21:43 GMT. All
figures in US dollars unless otherwise stated